Aliskirendoser på op til 600 mg eller det dobbelte af den højeste, anbefalede terapeutiske dosis er fundet at være veltolererede i kontrollerede kliniske forsøg.
The change in plasma levels of aliskiren in the presence of ketoconazole is expected to be within the range that would be achieved if the dose of aliskiren were doubled; aliskiren doses of up to 600 mg, or twice the highest recommended therapeutic dose, have been found to be well tolerated in controlled clinical trials.